Guillermo torre amione biography of abraham

By subscribing you agree to with our Privacy Policy. Investor Resources. No items found. Join our newsletter Sign up to receive the latest news from Cardiol Therapeutics! He then moved to Houston to complete his internship, residency, and cardiology fellowship at Baylor College of Medicine, where he received his first academic appointment as a clinical instructor in Torre-Amione has published more than manuscripts in peer-review journals and currently divides his time between his clinical and academic activities in Houston at The Methodist Hospital and in Monterrey, Mexico, at ITESM.

Guillermo Torre-Amione.

Guillermo torre amione biography of abraham

Chairman at Cardiol Therapeutics. Org chart. This person is not in the org chart. In his time at Methodist Hospital in Houston, Dr. Torre Amione was the Director of the Heart Failure Research Laboratory and conducted research on the mechanisms of immune activation and inflammation as it relates to myocardial dysfunction in the areas of heart failure and cardiac transplantation [6].

Torre-Amione and his colleagues have conducted numerous studies that suggest novel immune modulatory therapies for the treatment of heart failure. Other studies underway in the Heart Failure Research Laboratory are investigating additional immune response pathways that contribute to the progression of heart failure, particularity the role of B-cells in the progression of fibrosis and pathological hypertrophy.

Due to his multiple indexed publications, Dr. Torre Amione is now a level 3 member of the National Network of Research SNI [7] [ circular reference ] , a government organization that ranks active scientists in Mexico [8]. His research interests have led to several patents in the field of heart failure, over clinical research projects funded and the publication of more than peer-reviewed indexed articles.

This article "Guillermo Torre-Amione" is from Wikipedia. Recent changes. EverybodyWiki in another language. More languages. Sponsored articles Coming soon. Create account.